Information om | Engelska ordet CD3

Exempel på hur man kan använda CD3 i en mening

• CD3 (immunology), an antigen, cluster of differentiation protein (immunology), part of the T cell receptor (TCR) complex on a mature T lymphocyte.
• Another criticism of the McDonald criteria is that the definition of "lesions typical of MS" is unclear; a 2013 review identified the following characteristics: specific cell morphology shown by hematoxylin, demyelination shown by Luxol fast blue, macrophage appearance by KiM1P or CD68, damage to the axons shown by Bielschowsky stain, astrocytopathy shown by glial fibrillary acidic protein, and different lymphocyte subtypes, reacting to CD3, CD4, CD8, CD20 and CD138.
• The CD4 or CD8 proteins on the T-cell surface form a complex with the CD3 protein, which can then recognize the MHC.
• In December 2014, the company announced it would co-develop MacroGenics cancer drug candidate (MGD011) which targets both CD19 and CD3 proteins in treating B-cell malignant tumours.
• New anticancer drug treatments are being developed based upon the CD3 T cell co-receptor, with molecules being designed for altering the co-stimulatory signal to help get the T-cell to recognize the cancer cell and become fully activated.
• the tyrosine kinase Lck which is associated with co-receptors CD4 and CD8: is engaged to phosphorylate the CD3 coreceptor complex and ζ-chains of the TCR and to recruit and activate the ζ-chain- associated protein Zap70.
• Lck is moved near the CD3 complex and phosphorylates the tyrosines in the immunoreceptor tyrosine-based activation motifs (ITAMS), creating a docking site for ZAP-70.
• In September 2012, Saez released the album Messina, a triple album with the separate titles Les Échoués (CD1), Sur les quais (CD2) and Messine (CD3).
• Diagnosis is based on the clinical examination and on laboratory findings showing leukopenia, severe lymphopenia with low CD3, CD4, and CD8 counts and variable B cell function and immunoglobulin levels.
• Otelixizumab is one of several investigational monoclonal antibodies that target CD3, a T lymphocyte receptor involved in normal cell signaling.
• CD100 increases PMA, CD3 and CD2 induced T cell proliferation, increases CD45 induced T cell adhesion, induces B cell homotypic adhesion and down-regulates B cell expression of CD23.
• LCK then phosphorylate tyrosines in the CD3 complex creating a docking site for the SH2 domain of the SYK family kinase ZAP70, which is there phosphorylated too.
• Immunophenotyping or the neoplastic large B cells in these lesions shows that they express CD20 but not CD3 surface membrane B cell marker proteins.
• 1, B220, TER-119, and Gr-1 in mice and CD3 (T lymphocytes), CD14 (Monocytes), CD16 (NK cells, granulocytes), CD19 (B lymphocytes), CD20 (B lymphocytes), and CD56 (NK cells) in humans.
• A trifunctional antibody is a monoclonal antibody with binding sites for two different antigens, typically CD3 and a tumor antigen, making it a type of bispecific monoclonal antibody.
• Antibodies specific for CD3 such as teplizumab and otelixizumab show increased specificity for T cells compared to ATG and alemtuzumab, but are still associated with infection and cytokine release syndrome.
• On plasma membrane of a T cell there is the T-cell receptor (consists of α,β chains and multiple CD3 adaptor proteins), as well as molecules that induce signalling (tyrosine kinase Lck phosphorylates ITAMs in CD3 complex) and factors that inhibit signalling (tyrosine phosphatases CD45 and CD148).
• While there are positive markers for CAFs, there are also negative markers namely; cytokeratin and CD3, as CAFS do not have epithelial and endothelial characteristics.
• These include: ofatumumab, a monoclonal antibody that is stronger than rituximab in binding to CD20; two radioimmunotherapy monoclonal antibodies, Ibritumomab tiuxetan and Tositumomab that bind CD20 to deliver radiation from their attached radioactive isotopes to and kill CD20-bearing cells; lumiliximab, a monoclonal antibody that binds to CD23; dacetuzumab, a monoclonal antibody that binds CD40; Siglec-3 a monoclonal antibody that binds CD33; blinatumomab, a monoclonal antibody that binds both CD3 and CD19; chimeric antigen receptor T cell therapy using CD19-directed CAR-T cells; and lenalidomide, a drug with multiple anti-tumor actions.
• Talquetamab is a bispecific antibody against two targets: human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen with potential antineoplastic activity.

Förberedelsen av sidan tog: 173,43 ms.